Brought to you by 
Pulmatrix sells $15.5mm in Series B preferred shares; later completes round at $30.3mm
15 Jun 2011
Executive Summary
Pulmatrix (developing therapeutics to treat infectious and progressive respiratory diseases) has raised $15.5mm through the sale of Series B preferred shares to a group of ten investors. Arch Venture Partners and Novartis Bioventures Fund led (and each contribute one board member) and were joined by current backers Polaris Venture Partners and 5AM Ventures, among others. According to the company's Form D, it could bring in up to $30.3mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pulmatrix sells $15.5mm in Series B preferred shares; later completes round at $30.3mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice